Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2010

01-07-2010 | Clinical Trial Report

STEPP for the EGFR Inhibitor–Induced Rash—Definitely a Step in the Right Direction

Authors: Shawnta Coleman, Aminah Jatoi

Published in: Current Oncology Reports | Issue 4/2010

Login to get access

Excerpt

Lacouture ME, Mitchell EP, Piperdi B, et al.: Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:1351–1357. …
Literature
1.
Solomon BM, Jatoi A: Rash from EGFR inhibitors: opportunities and challenges for palliation. Curr Oncol Rep 2008, 10:304–308.CrossRefPubMed
2.
Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Oncology 2007, 21:34–36.PubMed
3.
Scope A, Agero AL, Dusza SW, et al.: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25:5390–5396.CrossRefPubMed
4.
Jatoi A, Rowland K, Sloan JA, et al.: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008, 113:847–853.CrossRefPubMed
Metadata
Title
STEPP for the EGFR Inhibitor–Induced Rash—Definitely a Step in the Right Direction
Authors
Shawnta Coleman
Aminah Jatoi
Publication date
01-07-2010
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 4/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0102-7

Other articles of this Issue 4/2010

Current Oncology Reports 4/2010 Go to the issue

ReviewPaper

The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?

ReviewPaper

Lung Cancer Screening: An Update, Discussion, and Look Ahead

ReviewPaper

Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety

ReviewPaper

Testicular Cancer: When Less is More

ReviewPaper

How to Discuss Errors and Adverse Events with Cancer Patients

ReviewPaper

Stratifying Osteosarcoma: Minimizing and Maximizing Therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits